Oxygen diffusion-enhancing compound

[1][2] Such conditions include hemorrhagic shock, myocardial infarction (heart attack), and stroke.

[1] Diffusion Pharmaceuticals is currently investigating the use of trans sodium crocetinate in the treatment of COVID-19, acute stroke, and solid cancerous tumors.

[8] Oxygen diffusion-enhancing compounds are thought to act by exerting hydrophobic forces that interact with water molecules.

[9] These interactions result in greater hydrogen bonding among water molecules, which constitute the majority of the blood plasma medium.

[9][13] Computer simulations have shown that TSC specifically can increase the transport of oxygen through water by as much as 30 percent.